CN109568481A - A kind of Chinese prescription preparation for treating coronary heart disease - Google Patents

A kind of Chinese prescription preparation for treating coronary heart disease Download PDF

Info

Publication number
CN109568481A
CN109568481A CN201710895859.7A CN201710895859A CN109568481A CN 109568481 A CN109568481 A CN 109568481A CN 201710895859 A CN201710895859 A CN 201710895859A CN 109568481 A CN109568481 A CN 109568481A
Authority
CN
China
Prior art keywords
parts
radix
chinese prescription
heart disease
prescription preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710895859.7A
Other languages
Chinese (zh)
Inventor
何贵杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TONGYITANG PHARMACEUTICAL CO Ltd
Original Assignee
TONGYITANG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TONGYITANG PHARMACEUTICAL CO Ltd filed Critical TONGYITANG PHARMACEUTICAL CO Ltd
Priority to CN201710895859.7A priority Critical patent/CN109568481A/en
Publication of CN109568481A publication Critical patent/CN109568481A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/586—Turtles; Tortoises, e.g. terrapins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285—Aucklandia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a kind of Chinese prescription preparations for treating coronary heart disease, it belongs to Chinese prescription preparation.Chinese prescription preparation includes formula as below: 1-6 parts of tortoise plastron, 1-6 parts of turtle shell, 1-10 parts of American Ginseng, 1-10 parts of Radix Notoginseng, 1-6 parts of west safflower, 1-10 parts of Radix Salviae Miltiorrhizae, 1-12 parts of rhizoma acori graminei, 1-10 parts of radix aucklandiae, 1-15 parts of endothelium corneum gigeriae galli, 1-5 parts of the shell of seaear, 1-3 parts of oyster, 1-6 parts of radix scutellariae, 1-10 parts of radix rehmanniae recen, 1-10 parts of the vine of multiflower knotweed, 1-6 parts of corydalis tuber, Radix Ophiopogonis 1-6 part, 1-6 parts of mother-of-pearl, 1-6 parts of cortex albiziae, 1-6 parts of uncaria, 1-10 parts of motherwort, 1-9 parts of cortex moutan, 1-6 parts of Caulis et Folium piperis, 1-10 parts of pueraria lobata, 1-10 parts of ilex pubescens, 1-15 parts of Pollen Typhae.This preparation can improve patients with coronary heart disease angina pectoris attacks rate and sleep quality, mitigate fluctuation of blood pressure, control blood pressure stabilization, medicinal material is at low cost, curative for effect, Small side effects.

Description

A kind of Chinese prescription preparation for treating coronary heart disease
Technical field:
The present invention relates to a kind of Chinese prescription preparations for treating coronary heart disease, belong to field of medicine preparing technology.
Background technique:
With the development and the improvement of people's living standards of social economy, the disease incidence of coronary heart disease is risen year by year, to the mankind Health constitute great threat, and bring heavy financial burden to society and family.
Modern medicine believes that, coronary atherosclerosis is the coefficient disease of many reasons, hypertension is wherein pole Important factor.
(1) hypertension is the independent risk factor of coronary heart disease: numerous studies figure is bright, and hypertension can be with damaged arteries endothelium And cause atherosclerosis, and accelerate Atherosclerosis.Blood pressure level is higher, and Degree of arteriosclerosis is heavier, dies of The risk of coronary heart disease is higher.
(2) hypertension can cause myocardial infarction: when there are Coronary Artery Lesions, blood pressure raising may trigger atherosis Plaque rupture, thrombosis block coronary artery, lead to acute myocardial infarction.Therefore, hypertension, which is well controllled, can prevent coronary disease Disease reduces coronary heart attack and can prevent accident.
Patients with coronary heart disease recognizes the risk of complicated hypertension insufficient at present, and controlling of blood pressure is very unstable.But coronary disease The specific pathogenesis of sick complicated hypertension is extremely complex, and pathogenesis is still not clear, and controls to coronary heart disease with hypertension Aspect is treated, doctor trained in Western medicine often uses drug combination, and long-term efficacy is bad, and side effect is very big, and traditional Chinese medical herbal treatment approach embodies Safely and effectively, the advantages such as toxic side effect is smaller are the important channels of coronary heart disease with hypertension treatment.
Therefore, Chinese prescription preparation of the invention treats coronary heart disease and the drug phase of hypertensive patient with current on the market Than prominent feature is can significantly improve the angina pectoris attacks rate of patients with coronary heart disease and sleep quality at the same time it can also aobvious The fluctuation for improving blood pressure is write, the stabilization of blood pressure is controlled, prescription is at low cost, curative for effect, Small side effects, has good society's meaning Justice and economic benefit.
Summary of the invention:
In view of the above-mentioned problems, the technical problem to be solved in the present invention is to provide a kind of Chinese prescription systems for treating coronary heart disease Agent, its prescription is at low cost, curative for effect, Small side effects.
The Chinese prescription preparation for the treatment of coronary heart disease of the invention includes the formula composition of following parts by weight: 1-6 parts of tortoise plastron, 1-6 parts of turtle shell, 1-10 parts of American Ginseng, 1-10 parts of Radix Notoginseng, 1-6 parts of west safflower, 1-10 parts of Radix Salviae Miltiorrhizae, 1-12 parts of rhizoma acori graminei, radix aucklandiae 1- 10 parts, 1-15 parts of endothelium corneum gigeriae galli, 1-5 parts of the shell of seaear, 1-3 parts of oyster, 1-6 parts of radix scutellariae, 1-10 parts of radix rehmanniae recen, 1-10 parts of the vine of multiflower knotweed, 1-6 parts of corydalis tuber, Radix Ophiopogonis 1-6 part, 1-6 parts of mother-of-pearl, 1-6 parts of cortex albiziae, 1-6 parts of uncaria, 1-10 parts of motherwort, cortex moutan 1-9 Part, 1-6 parts of Caulis et Folium piperis, 1-10 parts of pueraria lobata, 1-10 parts of ilex pubescens, 1-15 parts of Pollen Typhae.
Further preferably, the Chinese prescription preparation of the treatment coronary heart disease includes following parts by weight formula: tortoise plastron 5 Part, 5 parts of turtle shell, 8 parts of American Ginseng, 8 parts of Radix Notoginseng, 5 parts of west safflower, 8 parts of Radix Salviae Miltiorrhizae, 10 parts of rhizoma acori graminei, 8 parts of radix aucklandiae, 12 parts of endothelium corneum gigeriae galli, 4 parts of the shell of seaear, 2 parts of oyster, 5 parts of radix scutellariae, 9 parts of radix rehmanniae recen, 8 parts of the vine of multiflower knotweed, 5 parts of corydalis tuber, 5 parts of Radix Ophiopogonis, 5 parts of mother-of-pearl, silk tree 5 parts of skin, 5 parts of uncaria, 8 parts of motherwort, 8 parts of cortex moutan, 5 parts of Caulis et Folium piperis, 8 parts of pueraria lobata, 8 parts of ilex pubescens, 12 parts of Pollen Typhae.
It is of the present invention treatment coronary heart disease Chinese prescription preparation the preparation method comprises the following steps:
Step 1: first by Chinese prescription preparation according to parts by weight formulation ratio then by American Ginseng, Radix Notoginseng, western red 70 DEG C of flower, Radix Salviae Miltiorrhizae, rhizoma acori graminei, radix aucklandiae, endothelium corneum gigeriae galli dryings crushed 100 mesh or more, high temperature and humidity is gone out to moisture content≤5% Bacterium is that fine medicinal material powder is spare, remaining medicinal material adds 8-10 times of water to extract 2 times, every time 2 hours；Merging filtrate, being concentrated is 1.22 or so Medicinal extract；
Step 2: the medicinal material extract medicinal extract mixing for taking step 1 to prepare, admixes the above fine medicinal material powder of 100 mesh, mixes, with refining Honey plus hydration stick together pill, dry, are coated polishing, pill to get.
Beneficial effects of the present invention: the preparation of Chinese medicine preparation is simple, this Chinese prescription preparation is refined using common Chinese medicinal material It forms.This preparation can be taken for a long time, play and palliate the agonizing sufferings to patients with coronary heart disease, stablize the state of an illness, prevention or the effect for reducing breaking-out, Improve the life quality of patient.Chinese medicine composing prescription preparation selected materials are all traditional Chinese medicine material, without side-effects.Of the invention Medicine source is easy to get, and medicinal material is at low cost, largely alleviates the financial burden of patient.
Detailed description of the invention:
Fig. 1 is rat each group heart rate, angiosthenia, left room end diastolic pressure and electrocardio in pharmacodynamic study of the embodiment of the present invention The comparison figure of ST sections of figure；
Fig. 2 is pharmacodynamic study of embodiment of the present invention rat each group left ventricular systolic pressure and its maximum up and down rate Compare figure；
Fig. 3 is that each pair of rat carries out after large dosage of isoprel is subcutaneously injected in pharmacodynamic study of the embodiment of the present invention Electrocardiogram；
Fig. 4 is the experimental data comparative diagram of the high middle dose group of rat in pharmacodynamic study of the embodiment of the present invention；
Fig. 5 is high dose in pharmacodynamic study of the embodiment of the present invention to the whole blood contrast viscosity of the high, medium and low shear of normal rat And red blood cell influences datagram；
Fig. 6 is high dose in pharmacodynamic study of the embodiment of the present invention to inhibition platelet aggregation rate data in normal rat Figure.
Specific embodiment:
Present embodiment is described in further detail invention using following technical scheme and embodiment.
The Chinese prescription preparation for the treatment of coronary heart disease described in present embodiment includes following parts by weight formula: tortoise 1-6 parts of first, 1-6 parts of turtle shell, 1-10 parts of American Ginseng, 1-10 parts of Radix Notoginseng, 1-6 parts of west safflower, 1-10 parts of Radix Salviae Miltiorrhizae, rhizoma acori graminei 1-12 Part, 1-10 parts of radix aucklandiae, 1-15 parts of endothelium corneum gigeriae galli, 1-5 parts of the shell of seaear, 1-3 parts of oyster, 1-6 parts of radix scutellariae, 1-10 parts of radix rehmanniae recen, the tuber of multiflower knotweed 1-10 parts of rattan, 1-6 parts of corydalis tuber, Radix Ophiopogonis 1-6 part, 1-6 parts of mother-of-pearl, 1-6 parts of cortex albiziae, 1-6 parts of uncaria, 1-10 parts of motherwort, 1-9 parts of cortex moutan, 1-6 parts of Caulis et Folium piperis, 1-10 parts of pueraria lobata, 1-10 parts of ilex pubescens, 1-15 parts of Pollen Typhae.
Further preferably, the Chinese prescription preparation of the treatment coronary heart disease includes following parts by weight formula: tortoise plastron 5 Part, 5 parts of turtle shell, 8 parts of American Ginseng, 8 parts of Radix Notoginseng, 5 parts of west safflower, 8 parts of Radix Salviae Miltiorrhizae, 10 parts of rhizoma acori graminei, 8 parts of radix aucklandiae, 12 parts of endothelium corneum gigeriae galli, 4 parts of the shell of seaear, 2 parts of oyster, 5 parts of radix scutellariae, 9 parts of radix rehmanniae recen, 8 parts of the vine of multiflower knotweed, 5 parts of corydalis tuber, 5 parts of Radix Ophiopogonis, 5 parts of mother-of-pearl, silk tree 5 parts of skin, 5 parts of uncaria, 8 parts of motherwort, 8 parts of cortex moutan, 5 parts of Caulis et Folium piperis, 8 parts of pueraria lobata, 8 parts of ilex pubescens, 12 parts of Pollen Typhae.
The Chinese prescription preparation for the treatment of coronary heart disease described in present embodiment the preparation method comprises the following steps: Step 1: first By Chinese prescription preparation according to parts by weight formulation ratio then by American Ginseng, Radix Notoginseng, west safflower, Radix Salviae Miltiorrhizae, rhizoma acori graminei, radix aucklandiae, 70 DEG C of dryings of endothelium corneum gigeriae galli crushed 100 mesh or more to moisture content≤5%, and high temperature and humidity sterilizing is that fine medicinal material powder is spare, Remaining medicinal material adds 8-10 times of water to extract 2 times, and 2 hours every time, the medicinal extract for 1.22 or so was concentrated in merging filtrate；
Step 2: the medicinal material extract medicinal extract mixing for taking step 1 to prepare, admixes the above fine medicinal material powder of 100 mesh, mixes, with refining Honey plus hydration stick together pill, dry, are coated polishing, pill to get.
Embodiment 1: Step 1: first by Chinese prescription preparation according to parts by weight formulation ratio then by 8 parts of American Ginseng, 8 parts of Radix Notoginseng, 5 parts of west safflower, 8 parts of Radix Salviae Miltiorrhizae, 10 parts of rhizoma acori graminei, 8 parts of radix aucklandiae, 12 parts of endothelium corneum gigeriae galli dry at 70 DEG C to moisture content ≤ 5%, it crushed 100 mesh or more, high temperature and humidity sterilizing is that fine medicinal material powder is spare, then by 5 parts of remaining medicinal material tortoise plastron, turtle shell 5 Part, 2 parts of oyster, 5 parts of radix scutellariae, 9 parts of radix rehmanniae recen, 8 parts of the vine of multiflower knotweed, 5 parts of corydalis tuber, 5 parts of Radix Ophiopogonis, 5 parts of mother-of-pearl, is closed 4 parts of the shell of seaear Joyous 5 parts of skin, 5 parts of uncaria, 8 parts of motherwort, 8 parts of cortex moutan, 5 parts of Caulis et Folium piperis, 8 parts of pueraria lobata, 8 parts of ilex pubescens, 12 parts of Pollen Typhae plus 8-10 times of water is extracted 2 times, and 2 hours every time, the medicinal extract for 1.22 or so was concentrated in merging filtrate；
Step 2: the medicinal material extract medicinal extract mixing for taking step 1 to prepare, admixes the above fine medicinal material powder of 100 mesh, mixes, with refining Honey plus hydration stick together pill, dry, are coated polishing, pill to get.
Embodiment
Acute toxicity test: with the medicine maximum concentration, maximum volume stomach-filling mouse, giving 2 times in one day, carries out to the medicine Maximum dosage-feeding test, the toxic reaction of the appearance of mouse after observation administration.As the result is shown: with pill 0.4g/ml, 0.5ml/ 10g gives 2 times in one day, and without an example death after stomach-filling mouse, activity is breathed, ingested, drinking water, fur and killing main after inspection Visually observing for internal organs, is showed no exception.It is 9g that the medicine, which recommends adult clinical daily dosage, and adult is equivalent to clinic based on 60kg 267 times of adult dosage.The medicine maximum dosage-feeding is tested without an example animal dead, also has no toxic reaction.
Long term toxicity test: investigational agent, the toxic reaction that animal occurs continuously are given in observation repeatedly.It is daily with the medicine respectively 3.8g/kg, 7.5g/kg, 15g/kg are equivalent to 25 times of adult daily dosage, 50 times, 100 times, basic, normal, high three dosage stomach-fillings Rat is given, continuous 12 weeks, continues observation 2 weeks after drug withdrawal.Observe each group rat administration during and be discontinued convalescence general status； 1/2 rat of inspection is killed in 24 hours each groups after the last administration, remaining rat kills inspection after being discontinued 2 weeks, carry out hematology, blood biochemical analysis Indexs measure, main organs naked eyes and pathologic examination.As the result is shown: during administration and convalescence the pill it is basic, normal, high Three dosage groups drink water, ingest, hair color, fecal character, activity etc. are showed no anomalous variation without an example rats death；Administration It is period and the indexs such as the convalescence pill low, middle and high dose groups rat body weight, feed consumption, hematology, biochemical, main Organ index is compared with blank control group, difference that there are no significant；Main organs visually observe no abnormality seen；Each master of high dose group Want histopathologic examination's no abnormality seen under internal organs light microscopic.Scheme the bright medicine without overt toxicity effect.
Pharmacodynamics research:
One, to the influence of myocardial ischemia-reperfusion injury
Dosage and grouping: SDSD rat 60,250-300g, 6 groups, every group 10 are randomly divided into.This experiment sets Chinese medicine group High, normal, basic 3 dosage groups of recipe object separately set saline control group, pseudo- operation group, positive drug Diaoxinxue Kang group.This medicine Clinic is intended with dosage being to take daily 9g, and adult average weight is calculated as 0.15g/kg with 60kg.Pharmacodynamic study rat oral gavage dosage point It Wei not 0.5g/kg, 1.0g/kg, 2.0g/kg.
Medication: according to 1.0ml/100g gastric infusion, 3 administration groups of Chinese prescription drug, dosage is respectively 0.5g/ kg,1.0g/kg,2.0g/kg.；Diaoxinxue Kang group 65mg/kg；Saline control group, pseudo- operation group give physiological saline, and 1 Day 1 time, continuous 3 days.1h after last dose liquid or salt water, performs the operation.
With 20% urethanes (urethane) 1g/kg ip, after anesthesia, left common carotid is separated, it will be filled with liver The plastic catheter of plain physiological saline (5u/ml) is inserted into artery, is connected in MS---302 bio signal through pressure transducer and records and analyzes System monitors arterial pressure.Right carotid is separated, intubation to left ventricle monitors left indoor pressure.Couple limbs simultaneously to lead Connection, traces II and leads electrocardiogram.Transtracheal intubation holds positive pressure artificial respiration, frequency 60 times/min, tidal volume 3.5ml.Then in chest 4-5 intercostal opens chest on the left of bone, opens pericardium, interts line at coronary artery left anterior descending branch between arterious cone and left auricle of heart, Set is effective for ligaturing and loosening coronary blood with plastic tube.
Post surgery stabilization 20min, following coronary artery occlusion 30min, then loosen.The only row operation of pseudo- operation group, is preced with without ligaturing Shape artery.Before blocking coronary artery, ischemic 15min, 30min, then fill 30min, 60min totally 5 time points, recorded heart rate, blood pressure, Left ventricular systolic pressure and its maximum climbing speed (+dp/dtmax), fall off rate (- dp/dtmax) there are also left room end diastolic pressure and the hearts Electrograph.
Fig. 1 and Fig. 2 datagram is bright: this medicine is to recovery angiosthenia, heart rate, left indoor pressure and its maximum up and down rate (±dp/dtmax) there is remarkable result, the recovery of ECG ST section and left room end diastolic pressure has certain effect.
Two, to the influence of myocardial ischemia in rats caused by large dosage of isoprel
SD rat 45, weight 220-280g, be randomly divided into saline control group, this medicine high (2g/kg), in (1g/ Kg), low dosage (0.5g/kg) group, Propranolol (inderal 10mg/kg) positive controls.Daily gastric infusion 1 time, continuous 3 Day.1h urethane (1g/kg) solution intraperitoneal injection of anesthesia after the last administration.Trace II lead, precordial leads (use V4Needle-shaped electricity On the inside of the 5th intercostal linea medioclavicularis of pole piercing left side subcutaneously) after electrocardiogram, isoproterenol hydrochloride injection is subcutaneously injected 4mg/kg, subsequent 5,10,20min record II lead, precordial leads electrocardiogram, measures ST field offset value, as myocardial ischemia journey The index of degree.It can be seen from figure 3 that this medicine is high, middle dosage is compared with saline control group, ECG ST section degrees of offset can be made to subtract It is few, play the role of significantly fighting a large amount of Induced By Isoprenaline myocardial ischemias.
Fig. 3 datagram is bright: to the myocardial ischemia that large dosage of Induced By Isoprenaline is subcutaneously injected, can make ECG ST section Offset is reduced.
Three, the influence of myocardial ischemia in rats is induced pituitrin
SD rat 50, weight 210-280g, be randomly divided into saline control group, this medicine high (2g/kg), in (1g/ Kg), low dosage (0.5g/kg) group, nitroglycerin (Mingxing Pharmaceutical Factory, Guangzhou 010602 batch) positive controls.First 4 groups fill daily Stomach is administered once, and continuous 3 days.1h after the last administration, with urethane (1g/kg) solution intraperitoneal injection of anesthesia.It is pierced into needle electrode Rat four limbs are subcutaneous, record II lead electrocardiogram.2mg/kg (1ml contains 5mg) is injected intraperitoneally in nitroglycerin injection single administration, It gives after being anesthetized.
Posterior pituitary injection (Shanghai biochemical-pharmaceutical factory 011017 batch) is injected intravenously to each group Rat Tongue respectively 0.6u (1ml)/kg, 0.5 after note, 1,2,3,5min record II lead electrocardiogram, the case where ST section of observation or T wave increase, inversion, Or have the cardiac arrhythmia person of appearance, then it is judged to myocardial ischemia.The mouse number that myocardial ischemia occurs according to each group, uses x2Examine group difference Conspicuousness.Fig. 4 datagram is bright: the high middle dose group of the medicine can fight intravenous injection pituitrin Myocardial Ischemia.
Four, to the influence of normal rat hemorheology
SD rat 50,250~300g of weight, half male and half female is randomly divided into saline control group, this medicine height (2g/ Kg), (1g/kg), low (0.5g/kg) dosage group and positive control drug Diaoxinxue Kang (65mg/kg) in.Every stomach is administered once, even It is 7 days continuous.
Morning next day takes a blood sample after the last administration, detects hemorheological property, and Fig. 5 datagram is bright: high dose can reduce normal big The whole blood contrast viscosity and hematocrit of the high, medium and low shear of mouse.
Five, to the influence of platelet aggregation
SD rat 50, grouping administration is identical as above-mentioned lectin from hemolymph test.Urethane is injected intraperitoneally in 0.5h after the last administration The anesthesia of (1g/kg) solution.Abdominal aortic blood about 3ml, it is anticoagulant by 9: 1 3.8% sodium citrate solution of addition, with 800 turns/min It is centrifuged 8min, is sucked out upper layer ecru suspension about 1ml, as PRP (platelet-rich plasma).Then it is centrifuged (4000rpm) again Few thrombocyte plasma (PPP) is made in 10min, Aspirate supernatant.Using turbidimetry, using ADP as inducer (final concentration of 4mol/ L maximum platelet aggregation rate) is measured.Fig. 6 datagram is bright: high middle dosage obviously inhibits platelet aggregation rate.
This test uses SD rat various acute myocardial infarction and ischemia model, shows that this medicine has protection cardiac muscle, reverses damage Effect reduces whole blood contrast viscosity and hematocrit, this medical instrument is prompted to have promoting blood circulationization wherein high middle dosage inhibits platelet aggregation The stasis of blood reduces thrombus, controls the pharmacological action of blood pressure.
Clinical efficacy:
Typical case citing:
(1) Mr. Wang, male, 58 years old, worker.Patient's precordialgia, it is often dizzy, it cannot alleviate after rest, admission diagnosis For coronary atherosclerotic heart disease and hypertension.Relapse rate breaking-out, takes Danshen Root dropping ball, captopril medicine for a long time, Can only the respite state of an illness, have the adverse reactions such as very big gastrointestinal tract.Patient starts to take Chinese materia medica preparation of the present invention afterwards, takes altogether 2 courses for the treatment of, angina pectoris seizure frequency significantly reduce, blood pressure stabilization.
(2) Chen, male, 63 years old, peasant.Patient feels discomfort uncomfortable in chest the year before, and local hospital checks Color Sonography discovery Whole-heartedly expand, atrium sinistrum 52mm, left ventricle 87mm, slight pulmonary hypertension, regional wall motion abnormality, left heart function subtracts Low, electrocardiogram shows myocardial ischemia.Since patient gets a small salary, the huge expenses for medicine of financial insolvency starts to take drug of the present invention, clothes After 3 courses for the treatment of of medicine, admission examination finds indices close to normal range (NR).
(3) Xu certain, male, 69 years old, 138~155/95~123mmHg of blood pressure.The chest that happens suddenly before patient 3 years is uncomfortable, arrives Hospital admission, coronary angiography has no narrow on inspection, electrocardiogram myocardial ischemia, and locality is diagnosed as coronary heart disease, and (the variability heart twists Bitterly).It takes 6 months angina pectoris attacks of Western medicine to be unable to control, there is 2-4 angina pectoris attacks daily, about 1 minute every time.Take this Invention Chinese materia medica preparation is taken medicine after 3 courses for the treatment of, and the indices such as blood lipid, blood pressure, blood viscosity are normal, without rebound phenomenon after drug withdrawal.
(4) Huang, female, 53 years old.Patient suffers from hypertension, hyperlipidemia, the blood viscosity high several years, after start atrial fibrillation, cardiac muscle occur The symptoms such as ischemic, chest distress, and in the cerebral infarction that happens suddenly the year before.Admission examination is the cerebral infarction caused by coronary heart disease, in many ways Treatment produces little effect.After start to take Chinese materia medica preparation of the present invention, take medicine after 4 courses for the treatment of, patient can live on one's own life, walk, blood Press blood lipid etc. back to normal.
(5) Lu, female, 46 years old.Patients' blood is higher, occurs pareordia discomfort repeatedly, alleviates after rest, take during 1 year Use Danshen Root dropping ball.Afterwards due to fatigue of working, the steaming bounce in self-induction chest, angina pectoris is aggravated, after go to see a doctor, heart rate 95 times/ Point, cardiac arrhythmia is not had an electro-cardiogram, and stethoscope heart sound is strong, is diagnosed as coronary heart disease accompanied with hypertension.Patient takes Chinese materia medica preparation of the present invention 4 courses for the treatment of, the state of an illness tend towards stability, follow-up no relapse.
The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention.The technology of the industry Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this The principle of invention, without departing from the spirit and scope of the present invention, various changes and improvements may be made to the invention, these changes Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its Equivalent circle.

Claims (3)

1. a kind of Chinese prescription preparation for treating coronary heart disease, it is characterised in that: the Chinese prescription preparation includes following weight Number formula: 1-6 parts of tortoise plastron, 1-6 parts of turtle shell, 1-10 parts of American Ginseng, 1-10 parts of Radix Notoginseng, 1-6 parts of west safflower, 1-10 parts of Radix Salviae Miltiorrhizae, 1-12 parts of rhizoma acori graminei, 1-10 parts of radix aucklandiae, 1-15 parts of endothelium corneum gigeriae galli, 1-5 parts of the shell of seaear, 1-3 parts of oyster, 1-6 parts of radix scutellariae, radix rehmanniae recen 1- 10 parts, 1-10 parts of the vine of multiflower knotweed, 1-6 parts of corydalis tuber, Radix Ophiopogonis 1-6 part, 1-6 parts of mother-of-pearl, 1-6 parts of cortex albiziae, 1-6 parts of uncaria, benefit mother 1-10 parts careless, 1-9 parts of cortex moutan, 1-6 parts of Caulis et Folium piperis, 1-10 parts of pueraria lobata, 1-10 parts of ilex pubescens, 1-15 parts of Pollen Typhae.
2. a kind of Chinese prescription preparation for treating coronary heart disease according to claim 1, it is characterised in that: the treatment hat The Chinese prescription preparation of heart trouble includes following parts by weight formula: 5 parts of tortoise plastron, 5 parts of turtle shell, 8 parts of American Ginseng, 8 parts of Radix Notoginseng, western red Spend 5 parts, 8 parts of Radix Salviae Miltiorrhizae, 10 parts of rhizoma acori graminei, 8 parts of radix aucklandiae, 12 parts of endothelium corneum gigeriae galli, 4 parts of the shell of seaear, 2 parts of oyster, 5 parts of radix scutellariae, radix rehmanniae recen 9 Part, 8 parts of the vine of multiflower knotweed, 5 parts of corydalis tuber, 5 parts of Radix Ophiopogonis, 5 parts of mother-of-pearl, 5 parts of cortex albiziae, 5 parts of uncaria, 8 parts of motherwort, 8 parts of cortex moutan, 5 parts of Caulis et Folium piperis, 8 parts of pueraria lobata, 8 parts of ilex pubescens, 12 parts of Pollen Typhae.
3. a kind of Chinese prescription preparation for treating coronary heart disease according to claim 1, it is characterised in that: the treatment hat The Chinese prescription preparation of heart trouble the preparation method comprises the following steps:
Step 1: first by Chinese prescription preparation according to parts by weight formulation ratio then by American Ginseng, Radix Notoginseng, west safflower, pellet Ginseng, rhizoma acori graminei, radix aucklandiae, 70 DEG C of dryings of endothelium corneum gigeriae galli to moisture content≤5%, crushed 100 mesh or more, and high temperature and humidity sterilizing is Fine medicinal material powder is spare, remaining medicinal material adds 8-10 times of water to extract 2 times, every time 2 hours；The leaching for 1.22 or so is concentrated in merging filtrate Cream；
Step 2: the medicinal material extract medicinal extract mixing for taking step 1 to prepare, admixes the above fine medicinal material powder of 100 mesh, mixes, with refined honey plus Hydration sticks together pill, dry, is coated polishing, pill to get.
CN201710895859.7A 2017-09-28 2017-09-28 A kind of Chinese prescription preparation for treating coronary heart disease Pending CN109568481A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710895859.7A CN109568481A (en) 2017-09-28 2017-09-28 A kind of Chinese prescription preparation for treating coronary heart disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710895859.7A CN109568481A (en) 2017-09-28 2017-09-28 A kind of Chinese prescription preparation for treating coronary heart disease

Publications (1)

Publication Number Publication Date
CN109568481A true CN109568481A (en) 2019-04-05

Family

ID=65912993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710895859.7A Pending CN109568481A (en) 2017-09-28 2017-09-28 A kind of Chinese prescription preparation for treating coronary heart disease

Country Status (1)

Country Link
CN (1) CN109568481A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771338A (en) * 2024-01-04 2024-03-29 南昌华太生物科技开发有限公司 Jin Danfu granule and its preparation method and application in treating lower limb edema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104435112A (en) * 2014-12-13 2015-03-25 黑龙江江恒医药科技有限公司 Soothing pill and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104435112A (en) * 2014-12-13 2015-03-25 黑龙江江恒医药科技有限公司 Soothing pill and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771338A (en) * 2024-01-04 2024-03-29 南昌华太生物科技开发有限公司 Jin Danfu granule and its preparation method and application in treating lower limb edema
CN117771338B (en) * 2024-01-04 2024-05-24 南昌华太生物科技开发有限公司 Jin Danfu granule, its preparation method and application in treating lower limb edema

Similar Documents

Publication Publication Date Title
CN102908513B (en) Application of traditional Chinese medicine composition in medicine for treating arrhythmia
CN101780227A (en) Traditional Chinese medicine composition for treating acute stroke and preparation method thereof
CN109568481A (en) A kind of Chinese prescription preparation for treating coronary heart disease
CN105833229A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction
CN103549072B (en) Vital energy-benefiting brain-boosting tea and preparation method thereof
CN102861232A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension
CN102204956B (en) Chinese medicinal composition used at stroke recovery period and preparation method thereof
CN102370735B (en) Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia
CN100496539C (en) Medicine for curing coronary artery disease and its preparation method
CN100431532C (en) Breviscapine and borneol constituted composite injection formulation and preparation method thereof
CN104161800B (en) It is a kind of to be used to treat Chinese medicine composition of angiocardiopathy and preparation method thereof
CN102309675B (en) Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome
CN101152247A (en) Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same
CN104069174B (en) A kind of pharmaceutical composition and its production and use
CN104306437B (en) A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof
CN101632783A (en) Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale
CN105833001B (en) Purposes of the SHENQI JIANGTANG KELI in diabetic cardiomyopathy medicine is prepared
CN104940554A (en) Chinese herbal composition for treating heart diseases
CN102614411B (en) Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof
CN101559162B (en) Application of traditional Chinese medicine composition in preparing medicament for curing slow arrhythmia
CN103961429B (en) Traditional Chinese medicine composition having effects of moving qi and invigorating blood circulation and preparation method thereof
CN103735618B (en) It is a kind of to treat sinus syndrome and coronary disease and angina pectoris, the Chinese medicine composition of arrhythmia cordis and its preparation method and application
CN110179868A (en) The Shenfu pharmaceutical composition for treating heart failure
CN102309674B (en) Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block
CN104107219A (en) Aerosol for treating coronary heart disease and angina pectoris and preparation process of aerosol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190405